EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy – a literature review

Hussam Elddin Nabeih Khasawneh, Hesham M Hassan, Amal Ali Alharbi, Wesam Taher Almagharbeh, Raed Fanoukh Aboqader Al-Aouadi, Kirandeep Kaur, Ramya Maranan, Hadeer M Farhan iD, Hamada Hashem, Mariam M Hassan, Stefan Bräse, Ahmed Al-Emam

RSC Advances · 2025 · 15 (48) · 40998-41047

DOI: 10.1039/d5ra03819g ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift RSC Advances, 2025. Verfasst von Hussam Elddin Nabeih Khasawneh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Engineering Department, Al-Huson University College, Al-Balqa' Applied University P.O. Box 19117 Al-Salt Jordan. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: King Khalid University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) is a validated oncogenic driver in numerous solid tumors, and resistance to first- and second-generation tyrosine kinase inhibitors continues to limit clinical outcomes.

Autor:innen und Institutionen

  • Chemical Engineering Department, Al-Huson University College, Al-Balqa' Applied University P.O. Box 19117 Al-Salt Jordan.
  • Department of Pathology, College of Medicine, King Khalid University P.O. Box 62529 Asir 61421 Saudi Arabia.
  • Department of Nursing Leadership and Education, Faculty of Nursing, University of Tabuk Tabuk Saudi Arabia.
  • Medical and Surgical Nursing Department, Faculty of Nursing, University of Tabuk Tabuk Saudi Arabia.
  • College of Medicine, Al-Ayen Iraqi University, AUIQ An Nasiriyah Iraq.
  • Department of Chemistry, Maharaja Ranjit Singh Punjab Technical University Bathinda 151001 Punjab India.

ORCID-Profile: Hadeer M Farhan

Förderung

  • King Khalid University

Zitieren

APA

Khasawneh, H. E. N., Hassan, H. M., Alharbi, A. A., Almagharbeh, W. T., Al-Aouadi, R. F. A., Kaur, K., Maranan, R., Farhan, H. M., Hashem, H., Hassan, M. M., Bräse, S., & Al-Emam, A. (2025). Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy – a literature review. RSC Advances, 15(48), 40998-41047. https://doi.org/10.1039/d5ra03819g

Vancouver

Khasawneh HEN, Hassan HM, Alharbi AA, Almagharbeh WT, Al-Aouadi RFA, Kaur K, et al. Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy – a literature review. RSC Advances. 2025;15(48):40998-41047. doi:10.1039/d5ra03819g

BibTeX
@article{Khasawneh2025,
  author = {Khasawneh, Hussam Elddin Nabeih and Hassan, Hesham M and Alharbi, Amal Ali and Almagharbeh, Wesam Taher and Al-Aouadi, Raed Fanoukh Aboqader and Kaur, Kirandeep and Maranan, Ramya and Farhan, Hadeer M and Hashem, Hamada and Hassan, Mariam M and Bräse, Stefan and Al-Emam, Ahmed},
  title = {Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy – a literature review},
  journal = {RSC Advances},
  year = {2025},
  volume = {15},
  number = {48},
  pages = {40998--41047},
  doi = {10.1039/d5ra03819g}
}
Kostenlos starten →